These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 25647867)

  • 1. DEA reschedules hydrocodone combination products as schedule II.
    J Mich Dent Assoc; 2014 Oct; 96(10):11. PubMed ID: 25647867
    [No Abstract]   [Full Text] [Related]  

  • 2. DEA reschedules hydrocodone, makes changes to controlled substance disposal.
    Traynor K
    Am J Health Syst Pharm; 2014 Nov; 71(22):1916-8. PubMed ID: 25349231
    [No Abstract]   [Full Text] [Related]  

  • 3. Schedules of controlled substances: rescheduling of hydrocodone combination products from schedule III to schedule II. Final rule.
    Drug Enforcement Administration, Department of Justice
    Fed Regist; 2014 Aug; 79(163):49661-82. PubMed ID: 25167591
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Better late than never: time to up-schedule hydrocodone combination products.
    Kolodny A
    Pain Med; 2013 Nov; 14(11):1627-8. PubMed ID: 24238352
    [No Abstract]   [Full Text] [Related]  

  • 5. FDA to propose hydrocodone reclassification.
    J Calif Dent Assoc; 2014 Jan; 42(1):10. PubMed ID: 25080676
    [No Abstract]   [Full Text] [Related]  

  • 6. FDA advisers support rescheduling of hydrocodone products.
    Traynor K
    Am J Health Syst Pharm; 2013 Mar; 70(5):383-4. PubMed ID: 23413158
    [No Abstract]   [Full Text] [Related]  

  • 7. Schedules of controlled substances: rescheduling of buprenorphine from schedule V to schedule III. Final rule.
    Drug Enforcement Administration (DEA), Department of Justice
    Fed Regist; 2002 Oct; 67(194):62354-70. PubMed ID: 12369590
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rescheduling of combination hydrocodone products: problems for long-term care practitioners.
    Mattingly Ii TJ
    Consult Pharm; 2015 Jan; 30(1):13-9. PubMed ID: 25591027
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The downside of upscheduling.
    Gudin J; Lee AJ
    Pain Med; 2013 Nov; 14(11):1628-9. PubMed ID: 24238353
    [No Abstract]   [Full Text] [Related]  

  • 10. Hydrocodone prescriptions.
    Liewehr FR
    J Am Dent Assoc; 2013 Aug; 144(8):876. PubMed ID: 23904570
    [No Abstract]   [Full Text] [Related]  

  • 11. DEA reschedules hydrocodone combination products.
    Pergolizzi JV
    Pain Pract; 2015 Feb; 15(2):95-7. PubMed ID: 25639283
    [No Abstract]   [Full Text] [Related]  

  • 12. Recent issues regarding controlled substances.
    Helgeland D
    S D Med; 2013 Mar; 66(3):105, 107. PubMed ID: 23544298
    [No Abstract]   [Full Text] [Related]  

  • 13. FDA committee: More restrictions needed on hydrocodone combination products.
    Kuehn BM
    JAMA; 2013 Mar; 309(9):862. PubMed ID: 23462764
    [No Abstract]   [Full Text] [Related]  

  • 14. FDA advisory panel assesses hydrocodone prescription writing: every dentist's responsibility.
    Curro FA
    J Am Dent Assoc; 2013 May; 144(5):462-4. PubMed ID: 23633687
    [No Abstract]   [Full Text] [Related]  

  • 15. An empty toolbox: hydrocodone to schedule II.
    Berger BJ
    Ann Emerg Med; 2014 Dec; 64(6):19A-21A. PubMed ID: 25606604
    [No Abstract]   [Full Text] [Related]  

  • 16. Hydrocodone rescheduling.
    Wroten D
    J Ark Med Soc; 2014 Nov; 111(6):100. PubMed ID: 25654919
    [No Abstract]   [Full Text] [Related]  

  • 17. Author's response.
    Curro FA
    J Am Dent Assoc; 2013 Aug; 144(8):876-7. PubMed ID: 23904571
    [No Abstract]   [Full Text] [Related]  

  • 18. FDA panel recommends tighter rules for prescribing opioids.
    McCarthy M
    BMJ; 2013 Feb; 346():f1012. PubMed ID: 23412738
    [No Abstract]   [Full Text] [Related]  

  • 19. All hydrocodone products now schedule II drugs.
    J Am Vet Med Assoc; 2014 Nov; 245(9):992. PubMed ID: 25470841
    [No Abstract]   [Full Text] [Related]  

  • 20. Schedules of controlled substances; placement of 2,5-dimethoxy-4-(n)-propylthiophenethylamine and N-benzylpiperazine into Schedule I of the Controlled Substances Act. Final rule.
    Drug Enforcement Administration (DEA), Department of Justice
    Fed Regist; 2004 Mar; 69(53):12794-7. PubMed ID: 15029891
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.